Literature DB >> 8423238

Carrier detection in families with properdin deficiency by microsatellite haplotyping.

K Kölble1, A J Cant, A C Fay, K Whaley, M Schlesinger, K B Reid.   

Abstract

Human properdin deficiency is an X-linked disorder strongly predisposing to meningococcal disease which has been recorded in over 50 cases of various ethnic origins. Immunochemically, total deficiency (type I), partial deficiency (type II), and deficiency due to a dysfunctional molecule (type III) can be differentiated. It is therefore most likely that the causative molecular defects will show considerable genetic heterogeneity. Analysis of the properdin locus at Xp11.3-Xp11.23 has led to the characterization of two polymorphic (dC-dA)n.(dG-dT)n repeats located approximately 15 kb downstream from the structural gene. Three families (two Scottish Caucasoid, one Tunisian Sephardic) with seven deficient individuals were investigated immunochemically and using a nonradioisotopic polymerase chain reaction-based method for microsatellite detection. Probable and definite carriers frequently showed properdin levels which were in the normal range. No recombinants between the microsatellite loci and properdin deficiency were detected, thus allowing identification of the defective allele through the generations in all three pedigrees. Haplotyping for these highly polymorphic microsatellites in close physical linkage to the properdin gene can provide rapid and nonradioactive detection of carrier status and prenatal diagnosis without extensive sequencing analysis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423238      PMCID: PMC330001          DOI: 10.1172/JCI116207

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination.

Authors:  P Densen; J M Weiler; J M Griffiss; L G Hoffmann
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

2.  Familial properdin deficiency associated with chronic discoid lupus erythematosus.

Authors:  E R Holme; J Veitch; A Johnston; G Hauptmann; B Uring-Lambert; M Seywright; V Docherty; W N Morley; K Whaley
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

3.  Congenital properdin deficiency and meningococcal infection.

Authors:  H E Nielsen; C Koch
Journal:  Clin Immunol Immunopathol       Date:  1987-08

4.  Dysfunctional properdin in a Dutch family with meningococcal disease.

Authors:  A G Sjöholm; E J Kuijper; C C Tijssen; A Jansz; P Bol; L Spanjaard; H C Zanen
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

5.  Analysis of the natural polymeric forms of human properdin and their functions in complement activation.

Authors:  M K Pangburn
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

6.  Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction.

Authors:  J L Weber; P E May
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

7.  Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections.

Authors:  M Schlesinger; Z Nave; Y Levy; P E Slater; Z Fishelson
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

8.  Properdin deficiency with IgA nephropathy.

Authors:  R J Wyatt; B A Julian; J H Galla
Journal:  N Engl J Med       Date:  1981-10-29       Impact factor: 91.245

9.  Partial properdin deficiency.

Authors:  C A Davis; J Forristal
Journal:  J Lab Clin Med       Date:  1980-10

10.  A second variant of properdin deficiency: the detection of properdin at low concentrations in affected males.

Authors:  A G Sjöholm; C Söderström; L A Nilsson
Journal:  Complement       Date:  1988
View more
  1 in total

1.  Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency.

Authors:  C A Fijen; B H Derkx; E J Kuijper; M Mannens; S R Poort; M Peters; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.